logo-loader
viewMedexus Pharmaceuticals Inc

Full interview: Medexus Expands US assets by acquiring Aptevo Bio Therapeutics

Medexus Pharmaceuticals (CVE: MDP-OTCQB: PDDPF) CEO Ken d’Entremont joined Proactive's Steve Darling in Toronto with news the company has acquired Aptevo BioTherapeutics LLC, which owns the worldwide rights to the commercial hematology asset, IXINITY, for up-front cash consideration of approximately US$30 million.

d'Entremont tells Proactive why he feels this is a transformative acquisition and also how the company can increase Aptevo's already impressive revenue numbers.  

 

 

Quick facts: Medexus Pharmaceuticals Inc

Price: 2.5 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $35.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals pleased with recent Aptevo BioTherapeutics...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive he's pleased with the value the acquisition of hematology asset IXINITY has provided to Medexus, and that it is well positioned to emerge stronger when the economy reopens after the coronavirus crisis....

3 days, 19 hours ago

2 min read